Carrier-Free LSD1 Inhibitor Nanoassemblies for Anti-Tumor Therapy

Compound 17i, a promising LSD1 inhibitor with anti-tumor activity, was reformulated into PEGylated nanoassemblies to overcome solubility issues. The 811 KB PDF likely contains experimental data comparing the cytotoxicity, therapeutic efficiency, and immune response of the nanoassemblies versus the original solution in vitro and in BALB/c mice. The data was authored by Boao Li and published on figshare under a CC-BY-4.0 license in May 2026.

Use Cases

• Evaluate the cytotoxicity of LSD1 inhibitor nanoassemblies based on in vitro comparison data
• Assess therapeutic efficiency improvements in animal models based on results from CT-26 colorectal tumor-bearing mice
• Analyze anti-tumor immune response modulation based on immunological data mentioned in the description
• Compare systemic toxicity profiles between nanoassemblies and drug solutions based on animal study results

Strengths

• The dataset is associated with a specific, novel drug delivery method: carrier-free supramolecular nanoassemblies
• Experimental results include comparisons across multiple dimensions: cytotoxicity, therapeutic efficiency, immune response, and systemic toxicity
• The data is openly licensed (CC-BY-4.0) for reuse

Limitations

• The dataset is very small (811 KB), suggesting limited scope or a single study report
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare

Collection Method

Data likely gathered from laboratory experiments using the one-step nanoprecipitation method and in vivo studies in mice.

Freshness

Last updated 2026-05-21 11:33:39; freshness should be verified